The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS , July 11, 2024 /PRNewswire/ -- DelveInsight's ' Molecular Glues Competitive Landscape – 2024 ' report provides comprehensive global coverage of available, marketed, and pipeline molecular glues in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the molecular glues competitive domain. Key Takeaways from the Molecular Glues Competitive Landscape Report Over 10+ companies are evaluating 12+ molecular glues in various stages of development, and their anticipated acceptance in the oncology market would significantly increase market revenue.
Key molecular glues companies such as Bristol Myers Squibb , Monte Rosa Therapeutics Inc., Revolution Medicines Inc., Nurix Therapeutics, Nested Therapeutics, DeuteRx, and others are evaluating new molecular glues to improve the treatment landscape.
Promising molecular glues such as Mezigdomide, Golcadomide, Iberdomide, MRT-2359, RMC 6291, NX-2127, NST-628, SP-3164, and others are under different phases of molecular glues clinical trials. In May 2024 , Takeda Pharmaceuticals announced an exclusive licensing deal with China -based Degron Therapeutics to develop novel molecular glue degraders for various oncology, neuros.
